GlassScriptPhysician profile
Prabhat K Sinha
NPI 1235332172
$4,656.36
in general payments reported to CMS, 2019-2025
34 companies · $1,002 in 2025
The $1,002 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $605 · 2020: $526 · 2021: $575 · 2022: $359 · 2023: $644 · 2024: $944 · 2025: $1,002.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,474 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,474.03 |
| Education | $116.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,448.44 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $470.22 | 2019-2025 | Airsupra, Breztri, Tagrisso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $336.23 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Insmed, INC. | $214.83 | 2019-2025 | Arikayce, Brinsupri |
| Pulmonx Corporation | $194.67 | 2023-2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Inspire Medical Systems, INC. | $163.93 | 2024-2025 | Inspire |
| Sunovion Pharmaceuticals INC. | $163.46 | 2019-2020 | |
| Biomarin Pharmaceutical INC. | $153.78 | 2025 | Palynziq |
| Grifols USA, LLC | $138.11 | 2019-2023 | Prolastin-C Liquid |
| Actelion Pharmaceuticals US, INC. | $130.52 | 2019-2024 | Opsumit |
| United Therapeutics Corporation | $129.55 | 2019-2025 | Tyvaso, Tyvaso |
| Genzyme Corporation | $127.31 | 2022-2025 | |
| Philips North America LLC | $116.05 | 2020-2025 | Vest Therapy Und |
| Axsome Therapeutics, INC. | $109.12 | 2023-2025 | Sunosi |
| Sanofi-Aventis U.S. LLC | $99.95 | 2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $78.04 | 2022-2024 | Dupixent |
| Intuitive Surgical, INC. | $63.30 | 2024 | |
| Harmony Biosciences LLC | $61.77 | 2021 | |
| Merck Sharp & Dohme LLC | $58.03 | 2024 | Keytruda |
| Circassia INC. | $57.93 | 2019-2020 | |
| Viatris Specialty LLC | $52.28 | 2025 | Yupelri |
| Mylan Specialty L.P. | $50.88 | 2024 | Yupelri |
| Jazz Pharmaceuticals INC. | $36.39 | 2019-2020 | |
| Pfizer INC. | $30.48 | 2023-2024 | |
| Inogen, INC. | $29.31 | 2022 | |
| Avadel Cns Pharmaceuticals, LLC | $21.59 | 2024 | Lumryz |
| Amgen INC. | $21.35 | 2023 | Tezspire |
| Verona Pharma, INC. | $16.83 | 2025 | Ohtuvayre |
| Csl Behring | $15.80 | 2019 | |
| Electromed, INC. | $14.86 | 2019 | |
| Gilead Sciences, INC. | $13.85 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.35 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.46 | 2021 | |
| Veran Medical Technologies, INC. | $11.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prabhat Sinha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.